WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
NBA playoffs: Edwards leads Wolves to 98
Buildings shake briefly as earthquake rattles Taiwan
Pope Francis calls for ceasefire in Gaza and Ukraine in Easter message
Ohio judge to rule Monday on whether the state’s abortion ban stands
Chinese state media demands British Museum return 23,000 cultural relics
Trump asks appeals court to overturn ruling on Georgia prosecutor
Finnish police say bullying was motive for school shooting
Burglar hurled stolen mobile phones at police from the top of 60ft high roof during nine
HK's West Kowloon arts hub to run out of funds in 2025: CEO
Independent UN experts urge Yemen’s Houthis to free detained Baha'i followers
Governor, Congress members to meet over support for rebuilding bridge